Get the Stockscreener App
1.59
1.24%
-0.02
Pre-market:
1.66
0.07
+4.40%
Proqr Therapeutics N V stock is traded at $1.59, with a volume of 357.34K.
It is down -1.24% in the last 24 hours and up +41.96% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.
See More
Previous Close:
$1.61
Open:
$1.63
24h Volume:
357.34K
Relative Volume:
0.63
Market Cap:
$189.38M
Revenue:
$7.05M
Net Income/Loss:
$-30.43M
P/E Ratio:
-4.1975
EPS:
-0.3788
Net Cash Flow:
$21.84M
1W Performance:
-11.67%
1M Performance:
+41.96%
6M Performance:
-60.05%
1Y Performance:
-19.70%
1-Day Range:
$1.59
$1.70
1-Week Range:
$1.47
$1.80
52-Week Range:
$1.07
$4.62
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.59 | 189.38M | 7.05M | -30.43M | 21.84M | -0.3788 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-29-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
DAFNA Capital Management LLC Has $4.15 Million Stake in ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences - Yahoo Finance
Raymond James Financial Inc. Invests $260,000 in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Analysts Set ProQR Therapeutics (NASDAQ:PRQR) Price Target at $8.75 - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of “Buy” from Analysts - Defense World
ProQR: Q1 Earnings Snapshot - News-Times
1,181,413 Shares in ProQR Therapeutics (NASDAQ:PRQR) Acquired by ArrowMark Colorado Holdings LLC - MarketBeat
New Forecasts: Here's What Analysts Think The Future Holds For ProQR Therapeutics N.V. (NASDAQ:PRQR) - simplywall.st
ProQR Therapeutics NV earnings missed, revenue topped estimates By Investing.com - Investing.com Nigeria
ProQR Therapeutics N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
ProQR Therapeutics NV earnings missed, revenue topped estimates - Investing.com
ProQR (PRQR) Reports Q1 Revenue Growth and Strategic Milestones - GuruFocus
ProQR Reports Q1 2025 Financial Results Amid Rising R&D Costs - TipRanks
ProQR Therapeutics Advances Axiomer RNA Editing Pipeline with Leadership Appointments and Strong Financial Position - Nasdaq
ProQR Announces First Quarter 2025 Operating and Financial Results - GlobeNewswire
ProQR Therapeutics (PRQR) Expected to Announce Earnings on Thursday - MarketBeat
Invesco Ltd. Purchases Shares of 11,887 ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Analysts Issue Forecasts for PRQR FY2025 Earnings - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Shares Acquired by Boothbay Fund Management LLC - MarketBeat
ProQR Therapeutics N.V (NASDAQ: PRQR) Posted 2.58% Gain This Year: What’s Next? - Stocksregister
JPMorgan Chase & Co. Has $142,000 Holdings in ProQR Therapeutics (NASDAQ:PRQR) - Defense World
Evercore ISI Initiates Coverage on ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Therapeutics (NASDAQ:PRQR) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
ProQR Therapeutics NV expected to post a loss of 9 cents a shareEarnings Preview - TradingView
ProQR Announces Webcast of Presentation at the 2025 Citizens Lif - GuruFocus
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference | PRQR Stock News - GuruFocus
ProQR Announces Webcast of Presentation at the 2025 Citizens Life Sciences Conference - GlobeNewswire
RNA Editing Pioneer ProQR to Showcase Breakthrough Axiomer Platform at Major Healthcare Conference - Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) Earns Outperform Rating from Analysts at Evercore ISI - Defense World
ProQR Therapeutics (NASDAQ:PRQR) Research Coverage Started at Cantor Fitzgerald - Defense World
Adage Capital Partners GP L.L.C. Purchases 5,976,813 Shares of ProQR Therapeutics (NASDAQ:PRQR) - MarketBeat
ProQR Announces Annual General Meeting of Shareholders to be Held June 3, 2025 - The Manila Times
ProQR Therapeutics N.V [PRQR] Investment Appeal on the Rise - knoxdaily.com
RNA Editing Market Deep Research 2025-2032 | QIAGEN N.V., ProQR - openPR.com
Evercore ISI Group Initiates Coverage of ProQR Therapeutics N.V. (PRQR) with Outperform Recommendation - Nasdaq
ProQR Therapeutics assumed with an Overweight at Cantor Fitzgerald - Yahoo Finance
ProQR Therapeutics initiated with an Outperform at Evercore ISI - Yahoo Finance
XTX Topco Ltd Takes $163,000 Position in ProQR Therapeutics (NASDAQ:PRQR) - The AM Reporter
Riding the Waves: A Guide to Investing in PRQR Stock - investchronicle.com
Evercore ISI sets ProQR stock Outperform with $5 target By Investing.com - Investing.com India
ProQR Therapeutics (PRQR) Receives Overweight Rating and $8 Pric - GuruFocus
Cantor Fitzgerald sets $8 price target on ProQR shares with Overweight rating - Investing.com
ProQR Therapeutics (PRQR) Gains Outperform Rating from Evercore ISI | PRQR Stock News - GuruFocus
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):